...
首页> 外文期刊>Comparative clinical pathology >C-erbB-2 oncogene and p21~(WAF/CIP1) tumor suppressor gene expression as prognostic factors in canine mammary adenocarcinomas
【24h】

C-erbB-2 oncogene and p21~(WAF/CIP1) tumor suppressor gene expression as prognostic factors in canine mammary adenocarcinomas

机译:C-erbB-2癌基因和p21〜(WAF / CIP1)抑癌基因的表达作为犬乳腺腺癌的预后因素

获取原文
获取原文并翻译 | 示例

摘要

To evaluate the use of c-erbB-2 oncogene and p21~(WAF/CIP1) suppressor gene products as the prognosis markers for canine mammary tumors, expression of these gene products were examined immunohistochemically using tumor tissues and clinical data from 96 dogs with malignant mammary tumors. Semiquantitative data was compared with histopathological grades, proliferating cell nuclear antigen (PCNA)-positive index, and clinicopatho-logical matters. The expression c-erbB-2 protein was found in the cellular membrane and cytoplasm of neoplastic epithelial cells, and the positive index had no significant relation to the histopathological features and PCNA-positive index, except for the individual age of affected dogs (P<0.05). The product of p21~(WAF/CIP1) was mostly found in cytoplasm and occasionally in the nucleus of neoplastic cells. The quantitative data had significant association to the malignancy grade and size of tumors (P<0.05). However, that had no significant relationship to the PCNA-positive index. The present study concluded that both gene products could not apply as the direct markers to evaluate the prognosis of canine mammary tumors. The detection of c-erbB-2 product may be partly beneficial to the differential diagnosis of epithelial type of mammary cancer. The use of p21~(WAF/CIP1) product in prognosis of canine mammary cancer needs further investigation.
机译:为了评估c-erbB-2癌基因和p21〜(WAF / CIP1)抑制基因产物作为犬乳腺肿瘤预后标志物的作用,采用了肿瘤组织和来自96只恶性犬的临床资料,对这些基因产物的表达进行了免疫组织化学检查。乳腺肿瘤。将半定量数据与组织病理学等级,增殖细胞核抗原(PCNA)阳性指数和临床病理问题进行比较。在肿瘤上皮细胞的细胞膜和细胞质中发现了c-erbB-2蛋白的表达,其阳性指数与组织病理学特征和PCNA阳性指数没有显着关系,除了患犬的个体年龄(P < 0.05)。 p21〜(WAF / CIP1)的产物多见于细胞质中,偶见于赘生性细胞核中。定量数据与肿瘤的恶性程度和大小有显着相关性(P <0.05)。但是,这与PCNA阳性指数没有显着关系。本研究得出的结论是,这两种基因产物均不能用作评估犬乳腺肿瘤预后的直接标志物。 c-erbB-2产物的检测可能部分有助于上皮型乳腺癌的鉴别诊断。 p21〜(WAF / CIP1)产品在犬乳癌预后中的应用尚需进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号